ID: ALA4757124

Max Phase: Preclinical

Molecular Formula: C26H23ClF2N2O4

Molecular Weight: 500.93

Molecule Type: Unknown

Representations

Canonical SMILES:  O=C(O)Cc1cc(F)ccc1NC(=O)c1cccc(-c2cc(O[C@@H]3CCCNC3)c(Cl)cc2F)c1

Standard InChI:  InChI=1S/C26H23ClF2N2O4/c27-21-13-22(29)20(12-24(21)35-19-5-2-8-30-14-19)15-3-1-4-16(9-15)26(34)31-23-7-6-18(28)10-17(23)11-25(32)33/h1,3-4,6-7,9-10,12-13,19,30H,2,5,8,11,14H2,(H,31,34)(H,32,33)/t19-/m1/s1

Standard InChI Key:  FFEPTZHWLQHZBI-LJQANCHMSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 500.93

Molecular Weight (Monoisotopic): 500.1314

AlogP: 5.30

#Rotatable Bonds: 7

Polar Surface Area: 87.66

Molecular Species: ZWITTERION

HBA: 4

HBD: 3

#RO5 Violations: 2

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.57

CX Basic pKa: 9.43

CX LogP: 2.71

CX LogD: 2.71

Aromatic Rings: 3

Heavy Atoms: 35

QED Weighted: 0.41

Np Likeness Score: -1.00

References

1. Velcicky J,Wilcken R,Cotesta S,Janser P,Schlapbach A,Wagner T,Piechon P,Villard F,Bouhelal R,Piller F,Harlfinger S,Stringer R,Fehlmann D,Kaupmann K,Littlewood-Evans A,Haffke M,Gommermann N.  (2020)  Discovery and Optimization of Novel SUCNR1 Inhibitors: Design of Zwitterionic Derivatives with a Salt Bridge for the Improvement of Oral Exposure.,  63  (17): [PMID:32856916] [10.1021/acs.jmedchem.0c01020]

Source

Source(1):

• Scientific Literature